|
|||||
|
|
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase |
|
| Authors: | Koichi Takahashi MD Hagop M. Kantarjian MD Yulong Yang MD Koji Sasaki MD Preetesh Jain MD PhD Sara DellaSala BS Farhad Ravandi MD Tapan Kadia MD Naveen Pemmaraju MD Naval Daver MD Gautam Borthakur MD Guillermo Garcia‐Manero MD Elias Jabbour MD Jorge E. Cortes MD |
| Affiliation: | 1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas;2. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| Abstract: | |
| Keywords: | chronic myeloid leukemia (CML) chronic phase dasatinib nilotinib tyrosine kinase inhibitor |